Adrien Brulefert
Gencay, 86160, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Understanding the Mode of Action of Several Active Ingredients from the Micro-Immunotherapy Medicine 2LZONA®.
Journal: Journal of inflammation research
Published: October 11, 2024
In Vitro Study of Interleukin-6 when Used at Low Dose and Ultra-Low Dose in Micro-Immunotherapy.
Journal: Life (Basel, Switzerland)
Published: February 13, 2024
Understanding the Mode of Action of a Micro-Immunotherapy Formulation: Pre-Clinical Evidence from the Study of 2LEBV® Active Ingredients.
Journal: Life (Basel, Switzerland)
Published: November 10, 2023
The Unitary Micro-Immunotherapy Medicine Interferon-γ (4 CH) Displays Similar Immunostimulatory and Immunomodulatory Effects than Those of Biologically Active Human Interferon-γ on Various Cell Types.
Journal: International journal of molecular sciences
Published: January 28, 2022
Chikungunya Virus Envelope Protein E2 Provides a Vector for Targeted Antigen Delivery to Human Dermal CD14+ Dendritic Cells.
Journal: The Journal of investigative dermatology
Published: July 30, 2020
Inhibition of dengue virus infection by mannoside glycolipid conjugates.
Journal: Antiviral research
Published: December 21, 2017
Variation of the epidermal expression of glucocorticoid receptor-beta as potential predictive marker of bullous pemphigoid outcome.
Journal: Experimental dermatology
Published: August 31, 2017
Showing 1-8 of 8
Last Updated: 09/26/2026